NCT04291547 is a NA clinical trial of BALM in Low Mood, sponsored by University of York.

Who is sponsoring NCT04291547?

NCT04291547 is sponsored by University of York.

What drugs are being tested in NCT04291547?

Interventions in NCT04291547: BALM.

What condition does NCT04291547 study?

NCT04291547 studies Low Mood, Depression.

Is NCT04291547 still recruiting?

NCT04291547 is currently completed. Last updated 12 April 2021.

Last reviewed 2021-04-12 · How we verify

NCT04291547

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Computerised Behavioural Activation for Young People With Depression

Completed NA Last updated 12 April 2021

What this trial tests

NA trial testing BALM in Low Mood in 12 participants. Completed in 31 March 2021.

Timeline

10 June 2020

Primary endpoint
31 March 2021

31 March 2021

Quick facts

Lead sponsor	University of York
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	device feasibility
Enrollment	12
Start date	10 June 2020
Primary completion	31 March 2021
Estimated completion	31 March 2021
Sites	1 location across United Kingdom

Drugs / interventions tested

BALM

Conditions studied

Low Mood — all drugs for Low Mood →
Depression — all drugs for Depression →

Sponsor

University of York

Who can join

Adults 11 to 16, any sex, with Low Mood or Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this non-randomised feasibility study is to 1) examine the acceptability of a newly developed computerised Behavioural Activation programme (BALM) in treating young people experiencing low mood/depression and 2) assess the feasibility of undertaking a pilot Randomised Controlled Trial (RCT) of the intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of York trials

Trials by the same sponsor.

NCT04342715 — A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis · active not recruiting
NCT04104555 — Orthotics for Treatment of Symptomatic Flat Feet in Children · NA · completed
NCT04512742 — A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies · NA · completed
NCT04666662 — A Prognostic Model to PREDICT Relapse of Depression in Primary Care · completed
NCT03969134 — A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04291547 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of York
Last refreshed: 12 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04291547.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing